Ironwood Pharmaceuticals (IRWD) EBT Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 61.19% for Q1 2026.

• EBT Margin for Q1 2026 came in at 61.19%, up 14935.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2.85% (up 4791.0% YoY), and the FY2025 annual result was 30.77%, down 178.0% from the prior year.
• EBT Margin came in at 61.19% for Q1 2026 at Ironwood Pharmaceuticals, up from 336.83% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 67.41% in Q4 2022 to a low of 1002.24% in Q2 2023.
• The 5-year median for EBT Margin is 28.07% (2023), against an average of 71.11%.
• Across the five-year window, EBT Margin slumped 105755 bps in 2023 and jumped 102223 bps in 2024, its largest moves.
• Ironwood Pharmaceuticals' EBT Margin stood at 67.41% in 2022, then plunged by 348 bps to 166.88% in 2023, then advanced by 5 bps to 158.04% in 2024, then tumbled by 113 bps to 336.83% in 2025, then jumped by 118 bps to 61.19% in 2026.
• The last three EBT Margin figures came in at 61.19% (Q1 2026), 336.83% (Q4 2025), and 55.73% (Q3 2025), per Business Quant data.